News

Trial of PNH treatment ARO-C3 plans to start dosing patients this year

ARO-C3, an experimental treatment being developed for paroxysmal nocturnal hemoglobinuria (PNH) and other disorders mediated by the complement system, appears to be working as intended in a group of healthy volunteers. That’s according to interim data from an ongoing Phase 1/2 trial testing the Arrowhead Pharmaceuticals therapy in adults…

Soliris effective in PNH when properly prescribed: Study

Most people with paroxysmal nocturnal hemoglobinuria (PNH) benefited from Soliris (eculizumab) therapy when they adhered to strict treatment guidelines, a real-world Dutch study showed. Because most had an incomplete response, new therapies are needed to improve real-world outcomes, however, the study’s researchers suggested, and emphasized that their data could…